| Hazard Information | Back Directory | [Uses]
Motavizumab can prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV disease.
| [in vivo]
Motavizumab (intraperitoneal injection; 1.25 mg in 0.1 ml of PBS/per mouse; once) treatment shows reductions on RSV replication and concentrations of cytokine and chemokines in RSV-infected mice[1]. | Animal Model: | Seven-week-old female, pathogen-free BALB/c mice intranasally inoculated with 106.5 PFU RSV-A2[1] | | Dosage: | 1.25 mg in 0.1 ml of PBS/per mouse | | Administration: | Intraperitoneal injection; 1.25 mg in 0.1 ml of PBS/per mouse; once | | Result: | Resulted in significant reductions of RSV loads compared with untreated controls on days 1 and 5.
Showed lower BAL concentrations of IL-1α, IL-12p70, TNF-α and IFN-γ and serum IL-10 and KC compared with RSV-infected untreated mice. |
| [storage]
Store at -20°C |
|
| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Website: |
www.lgmpharma.com |
| Company Name: |
Biolab Reagents
|
| Tel: |
65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
|